Previous 10 | Next 10 |
BAUDETTE, Minn., Aug. 24, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 25 th Annual Global Investment Confere...
Shares of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) traded at a new 52-week high today and are currently trading at $63.32. So far today, approximately 41,404 shares have been exchanged, as compared to an average 30-day volume of 138.69k shares. ANI Pharmaceuticals, Inc., a biopharmaceutical c...
-- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy -- BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- A...
2023-08-17 06:40:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks aren’t for everyone. But if you want to dive into a sector that can potentially give you incredible returns, you’ll want to focus your search on A-rated biotech...
2023-08-09 13:45:02 ET ANI Pharmaceuticals, Inc. (ANIP) Q2 2023 Earnings Conference Call August 09, 2023, 08:30 AM ET Company Participants Judy DiClemente - Insight Communications IR Nikhil Lalwani - President and CEO Stephen Carey - CFO Conference Call Par...
2023-08-09 06:53:30 ET ANI Pharmaceuticals press release ( NASDAQ: ANIP ): Q2 Non-GAAP EPS of $1.28 beats by $0.61 . Revenue of $116.5M (+57.6% Y/Y) beats by $16.64M . Bright Health is revising its 2023 financial outlook to reflect the movement of our Californi...
Second Quarter 2023 Financial Results -- Record quarterly net revenues of $116.5 million, representing year-over-year growth of 57.8%; net income available to common shareholders of $5.8 million and diluted GAAP income per share of $0.29 -- -- Record quarterly adjusted non-GAA...
2023-08-08 14:52:50 ET ANI Pharmaceuticals ( NASDAQ: ANIP ) is scheduled to announce Q2 earnings results on Wednesday, August 9th, before market open. The consensus EPS Estimate is $0.67 (+415.4% Y/Y) and the consensus Revenue Estimate is $99.86M (+35.1% Y/Y). Over the...
BAUDETTE, Minn., July 31, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2023 financial results on Wednesday, August 9, 2023, prior to the market open. Ni...
2023-07-05 00:51:54 ET Summary ANIP Pharmaceuticals has not yet published a pipeline of products under development or out-licensed, leaving investors in the dark about future revenue opportunities. The company has a range of drugs in various stages of development, including treatm...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Po...
2024-07-09 17:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP....